ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Eyenovia Inc

Eyenovia Inc (EYEN)

0.7604
-0.0476
(-5.89%)
Closed June 03 4:00PM
0.7498
-0.0106
( -1.39% )
Pre Market: 5:42AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
0.7498
Bid
0.6693
Ask
0.8207
Volume
261
0.00 Day's Range 0.00
0.501 52 Week Range 3.1209
Market Cap
Previous Close
0.7604
Open
-
Last Trade Time
05:32:36
Financial Volume
-
VWAP
-
Average Volume (3m)
1,266,995
Shares Outstanding
44,122,225
Dividend Yield
-
PE Ratio
-1.23
Earnings Per Share (EPS)
-0.62
Revenue
4k
Net Profit
-27.26M

About Eyenovia Inc

Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precis... Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Eyenovia Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker EYEN. The last closing price for Eyenovia was $0.76. Over the last year, Eyenovia shares have traded in a share price range of $ 0.501 to $ 3.1209.

Eyenovia currently has 44,122,225 shares outstanding. The market capitalization of Eyenovia is $33.53 million. Eyenovia has a price to earnings ratio (PE ratio) of -1.23.

EYEN Latest News

Anticipation Builds on Wall Street for Federal Reserve’s Upcoming Policy Moves; WTI and Brent See Upticks

In Monday’s pre-market trading, U.S. index futures are mixed, with Wall Street in anticipation of the monetary policy guidelines that the Federal Reserve is expected to release during the...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.03855.412624771550.71130.830.675278710.76024081CS
4-0.1302-14.79545454550.881.080.677750890.83435298CS
12-0.8802-541.631.780.50112669950.85481257CS
26-0.6802-47.56643356641.432.570.5019629011.25268937CS
52-2.2302-74.83892617452.983.12090.5016276061.40264743CS
156-4.2802-85.09343936385.036.630.5013712262.25908153CS
260-4.2402-84.97394789584.997.720.5013273673.01654832CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MLGOMicroAlgo Inc
$ 4.75
(204.49%)
7.35M
CORZCore Scientific Inc
$ 7.36
(51.13%)
3.69M
ANNXAnnexon Inc
$ 6.07
(32.53%)
578.91k
PLTNPlutoniam Acquisition Corporation
$ 8.60
(29.91%)
527
ESGLESGL Holdings Ltd
$ 1.15
(21.05%)
61
ALBTAvalon GloboCare Corporation
$ 0.92
(-25.20%)
442.64k
HYWHywin Holdings Ltd
$ 0.5344
(-20.59%)
113.67k
YGMZMingZhu Logistics Holdings Limited
$ 0.3899
(-15.33%)
228.67k
NIVFNewGenIvf Group Ltd
$ 1.19
(-13.77%)
3.93k
JCSEJE Cleantech Holdings Limited
$ 1.05
(-13.22%)
4.64k
MLGOMicroAlgo Inc
$ 4.75
(204.49%)
7.35M
LUXHLuxUrban Hotels Inc
$ 0.3315
(7.63%)
5.03M
CORZCore Scientific Inc
$ 7.36
(51.13%)
3.69M
FFIEFaraday Future Intelligent Electric Inc
$ 0.6052
(-3.14%)
2.2M
CRKNCrown Electrokinetics Corporation
$ 0.1111
(-5.77%)
2.17M

EYEN Discussion

View Posts
Southern Gal Southern Gal 5 days ago
Picked up more today.
Time will tell...
👍️0
Southern Gal Southern Gal 6 days ago
I started buying today. Looking for $1
👍️0
Dennis14 Dennis14 2 months ago
I bought in today. Now I’ll sit and wait.
👍️0
Monksdream Monksdream 2 months ago
EYEN new 52 lo
👍️0
Monksdream Monksdream 2 months ago
EYEN new 52 lo
👍️0
Monksdream Monksdream 3 months ago
EYEN under $2
👍️0
Monksdream Monksdream 3 months ago
EYEN under $2
👍️0
glenn1919 glenn1919 3 months ago
EYEN..........................................https://stockcharts.com/h-sc/ui?s=EYEN&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 3 months ago
EYEN.......................................https://stockcharts.com/h-sc/ui?s=EYEN&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 3 months ago
EYEN under $2
👍️0
Monksdream Monksdream 7 months ago
EYEN new 52 week low
👍️0
Monksdream Monksdream 8 months ago
EYEN new 52 week low
👍️0
Monksdream Monksdream 8 months ago
EYEN under $2
👍️0
honest dave honest dave 3 years ago
EYEN --
--Northland Adjusts Eyenovia's Price Target to $9 From $12, Maintains Outperform Rating
BY MT Newswires
— 9:31 AM ET 10/26/2021
👍️0
jdlamont jdlamont 3 years ago
EYEN now trading options!!!!
👍️0
jdlamont jdlamont 3 years ago
EYEN now trading options!!!!
👍️0
beambe beambe 4 years ago
Good NEWS
👍️0
beambe beambe 4 years ago
good Volume
👍️0
beambe beambe 4 years ago
https://eyenovia.com/about-2019/

👍️0
ClayTrader ClayTrader 4 years ago
* * $EYEN Video Chart 08-11-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
beambe beambe 4 years ago
good Volume
👍️0
breezy1 breezy1 4 years ago
OCGN - .62 orphan FDA approvals
👍️0
crudeoil24 crudeoil24 4 years ago
Eyenovia and Arctic Vision Announce Exclusive Collaboration and License Agreement to Develop and Commercialize MicroPine and MicroLine in Greater China and South Korea
8:05 am ET August 11, 2020 (Globe Newswire) Print
Eyenovia Eligible to Receive up to a Total of $45.75 million in Upfront Payments and Development and Commercialization Milestones and Development Costs

Arctic Vision to Lead Expansion of Novel Approach to Treating Myopia and Presbyopia in Greater China and South Korea

Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP(TM)) therapeutics and Arctic Vision, a clinical stage biotech company focused on developing and commercializing innovative ophthalmology therapies in China and Asia, today announced that they have entered into an exclusive license agreement for Arctic Vision to develop and commercialize MicroPine for the treatment of progressive myopia and MicroLine for the treatment of presbyopia in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea.

Under the terms of the agreement, Eyenovia may receive up to a total of $45.75 million in upfront payments as well as additional payments, based on various development and regulatory milestones, including the initiation of clinical research and approvals in Greater China and South Korea, and development costs. In addition, Arctic Vision will purchase its supply of MicroPine and MicroLine from Eyenovia or, for such products not supplied by Eyenovia, pay Eyenovia a mid-single digit percentage royalty on net sales of such products, subject to certain adjustments. Eyenovia will pay a mid-double digit percentage of such payments, royalties, or net proceeds of such supply to its Asian licensee pursuant to the arrangement
👍️0
BioSpecialist BioSpecialist 4 years ago
next $10 stock soon
👍️0
BioSpecialist BioSpecialist 4 years ago
STRONG BUY
👍️0
BioSpecialist BioSpecialist 4 years ago
EYEN = MC $60 Million /NDA submission for BIG drug in Q3 / 2 more Drugs in Phase 3 including a potential Blockbuster /Undiscovered low float gem = A Potential 10+ Bagger Gem ..GLTA



👍️0
jdlamont jdlamont 4 years ago
anyone who sees the video of the kid using the machine will buy the stock.
So easy and simple to use-REVOLUTIONARY. Very impressive.
👍️0
ADVFN_bioking ADVFN_bioking 4 years ago
RALLLYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY
👍️0
ADVFN_bioking ADVFN_bioking 4 years ago
looks like next breakout about to start
👍️0
ADVFN_bioking ADVFN_bioking 4 years ago
Load up before she takes off again
👍️0
ADVFN_bioking ADVFN_bioking 4 years ago
STRONG BUY this pure undiscovered Goldmine
👍️0
JGCola JGCola 5 years ago
Down a lot today. I'd say related to ALDX (another "eyes" biotech) which is down about 32% following Top-Line results. It's a mistake to associate the faith of those 2 IMO. This is creating a great opportunity. Will go back over 4$ very soon and may never "look" back. This wild horse will suddenly run free at some point. Great MGT. Founder keeps on buying. Great innovation. First-in-class comes to mind.
👍️0
jdlamont jdlamont 5 years ago
4 years from now 300 dollar stock when myopia drug approved
👍️0
ADVFN_bioking ADVFN_bioking 5 years ago
UUUUUUUUUUUUUUUUUUUP again and still terrible undervalued
👍️0
ADVFN_bioking ADVFN_bioking 5 years ago
BOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOM
👍️0
ADVFN_bioking ADVFN_bioking 5 years ago
$20 stock trading at $3
👍️0
ADVFN_bioking ADVFN_bioking 5 years ago
mega potential here
👍️0
ADVFN_bioking ADVFN_bioking 5 years ago
could run fast
👍️0
ADVFN_bioking ADVFN_bioking 5 years ago
love it
👍️0
jdlamont jdlamont 5 years ago
Zacks raises stock to BUY today and there is nobody here. Wow.
👍️0
jdlamont jdlamont 5 years ago
olympus investments takes 70.000 share position
👍️0
jdlamont jdlamont 5 years ago
200k day, crazy trading swings. should be volume reversal, we shall see.
👍️0
jdlamont jdlamont 5 years ago
Company is a conduit for drug delivery for every topical eye care drug company in existence, and hence will be bought out.
👍️0
jdlamont jdlamont 5 years ago
Game of Rogues- 40 cent spread between bid and asked, no law in the Wild West.
👍️0
jdlamont jdlamont 5 years ago
The undiscovered country.
This is going to be the new application standard for all things eye.
One machine with multi-function use.
Enormous market. one of a kind tech with no competition, as they lead with multiple phase 3 trials, and small cap equals grand slam home run.
👍️0